RE:RE:New Raymond James analysis and Does anyone Know? Was this RJ report about the heart meds specific to CRDL?
RJ recently came out with an updated research report (March 19) that you can obtain if you are a shareholder. The analyst changed his 12 month target to $6.00 and stated revenue for 2020 would be $1 million.
Longer term I believe the FDA CBD ruling will help CRDL re various Heart treatments etc. but not in the immediate term as per the following:
“This ruling doesn’t have a seismic impact. It really only impacts GW Pharma,” said William Roark, co-chair of the Pennsylvania Bar Association’s Medical Marijuana and Hemp Law Committee. “It makes their product more accessible for patients. It means doctors don’t have to go through the drug-monitoring program to make certain their patients don’t have a drug history. And a parent will now be able to go from pharmacy to pharmacy rather than having one specific source.”